Ann: Client Outlook Acquisition and Capital Raise Presentation, page-23

This a common misconcpetion with small cap growth stocks i.e. CR = Dilutive & therefore detrimental to their investment. Incorrect
They are a necessity for any growth stock & to be fully expected & encouraged, in the right conditions.

I have seen a plethora or CR to just bolster the coffers & underaken in a fashion disrespectful to loyal shareholders who miss out.
Mach7 have proposed an agreeable SP at a decent discount to shareholders & most importantly its for some serious growth.
I have zero qualms. Its an excellent & shrewd acquisition that will propel us.

Key points I particuarly liked:
* Addressable market increase 272% with a unified sales pitch. Priceless.
* Pipeline - >50% to $150M! ($40M near term)
* ARR 70% increase to $14.75M

I will be subscribing to the 1-4 offer & probably close to the 50% additional entitlement, if available.
I see this as a game changer in the long term prospects for Mach7.

They mention Hyland Imaging is their main competitor but is not listed on the viewing specialists slide. Plenty of digging around to do.